Various authors have recently identified dopaminergic neurones and dopaminergic receptors in cerebral structures other than the nigrostriatal system-limbic system, some cortical and some hypothalamic-hypophyseal areas (Kebabian et al., 1972; Horn et al., 1974;  Sourkes, 1975; ClementCormier, 1977) . These observations suggest that the dopaminergic system may play, among other physiological activities, an important role in sleep.
We have studied sleep induction in man after administration of apomorphine. This drug, at the dose we have used, is a direct stimulant of the dopaminergic receptors at various levels, and it has been proved to induce sleep probably in relation to the stimulation of these non-emetic receptors (Sagales and Erril, 1975; Di Chiara et al., 1976; Corsini et al., 1977) .
We administered apomorphine to subjects with a variety of responsiveness of the dopaminergic systems. Three groups of 10 volunteer subjects have been investigated: normal control subjects, Parkinsonism patients before the beginning of any specific treatment, and Parkinsonism patients undergoing L-dopa therapy over a long period. One may suppose that these patients have different dopaminergic receptor responsiveness, in relation not only to the severity of the illness, but also to the chronic treatment with high doses of L-dopa (Barbeau, 1974; Pycock and Marsden, 1977; Lee et al., 1978) .
Siubjects and methods
The study was carried out on 10 normal control subjects (six men and four women) aged 46-67 years (mean=54+4-4.7) and on 20 patients with Parkinsonism. The last group was divided into two subgroups. The first consisted of 10 patients (six men and four women) aged 51-72 years (mean= 61.6-+5.5) on L-dopa plus carbidopa therapy for at least 18 months, with duration of illness varying from three to 20 years and a severity, rated on the Webster scale, ranging from 16 to 6 (mean= 12+ 2.6). The second group consisted of 10 patients (five men and five women) aged 50-61 years (mean =54.4+3.4), who had never been treated with L-dopa-their illness had lasted from five to 12 months, with a mean severity of 4+0.9 on the Webster scale.
The nature and purpose of the investigation were explained to the patients and control subjects, and their consent was obtained. Recordings of EEG, EMG (from submental muscle), electrooculogram, cardiac and respiration rates were made on each subject, beginning between 1600-1700 hr for three hours after subcutaneous injection of apomorphine (1.5 mg). Patients and control subjects were submitted to a similar experiment three days before apomorphine administration, but with saline injected as placebo.
Our selected apomorphine dose is the lowest emetic one in normal subjects, and it is also the dose which acts as stimulant to dopaminergic (DA) receptors (Duby et al., 1972; Tolosa and Sparber, 1974) . 458 The EEG was recorded from longitudinal inferior and vertex reference leads. The paper speed was 15 mm/second.
We recorded the appearance of vomiting and its latency, sleep onset latency, and stages of sleep.
Results
In all normal subjects apomorphine induced both vomiting and sleep (Table) Among the 10 Parkinsonism patients treated with L-dopa, apomorphine (1.5 mg) induced vomiting in two, and nausea in another one, while sleep was induced in three subjects but in only one with a latency comparable to that of the control subjects (Table) .
In the group of Parkinsonism patients who had never had L-dopa treatment and who had a less severe degree of disease, apomorphine induced vomiting and sleep with a mean latency of 23.7t 2.1 min (range 15-34 min) for vomiting and 29.8 +2.31 min (range 24-39 min) for sleep. The latencies were not significantly lower than in control subjects (Table) . Stages 3 and 4 sleep were quickly recorded and they lasted for about 34% of the recording time. In one case REM stage sleep occurred and the patient was wakened by the operator at the end of the third hour of registration.
Discussion
The role of dopamine and of substances acting on the dopaminergic system in sleep mechanisms has been investigated in animals (Kafi and Gaillard, 1976) and in humans (Sagales and Erill, 1975; Corsini et al., 1977) , but without explanation of the results.
In our study, apomorphine, at a dosage of 1.5 mg subcutaneously, induced in healthy volunteers, vomiting and sleep with latency, duration, and EEG patterns which were homogeneous in all subjects. Under the same experimental conditions, the drug did not induce either vomiting or sleep in seven of 10 patients suffering from Parkinson's disease who had been taking L-dopa for a long time. It is important to note that in patients of this group the drug did not provoke an improvement of the Parkinsonism symptoms, in contrast with observations reported in the literature (Duby et al., 1972) . Furthermore, in two of them with a severe degree of illness, and, therefore, receiving a bigger dosage of L-dopa, apomorphine induced some excitation.
In the normal subject, apomorphine induces vomiting by stimulating the dopaminergic receptors of the emetic centre in the medulla oblongata (Sourkes, 1975) ; it probably induces sleep by stimulating the hypothalamic-hypophyseal neuroendocrine centres.
The lack of response to apomorphine found in patients with severe Parkinsonism on treatment for a long time may be related to the treatment itself. Numerous observations, including the recent ones of Lee et al. (1978) show that long-term treatment with L-dopa reverses the supersensitivity phenomenon of the striatal dopaminergic re- 
